Literature DB >> 1721261

Pharmacokinetics of FK 506 in transplant patients.

R Venkataramanan1, A Jain, V S Warty, K Abu-Elmagd, M Alessiani, J Lever, A Krajak, J Flowers, S Mehta, S Zuckerman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1721261      PMCID： PMC2972732     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  13 in total

1.  Pharmacokinetics of FK 506: preclinical and clinical studies.

Authors:  R Venkataramanan; A Jain; E Cadoff; V Warty; K Iwasaki; K Nagase; A Krajack; O Imventarza; S Todo; J J Fung
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.

Authors:  R Venkataramanan; A Jain; V W Warty; K Abu-Elmagd; H Furakawa; O Imventarza; J Fung; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

3.  Measurement of FK 506 by HPLC and isolation and characterization of its metabolites.

Authors:  U Christians; C Kruse; R Kownatzki; H M Schiebel; R Schwinzer; M Sattler; R Schottmann; A Linck; V M Almeida; F Braun
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

4.  FK 506 inhibition of cyclosporine metabolism by human liver microsomes.

Authors:  G Omar; I A Shah; A W Thomson; P H Whiting; M D Burke
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

5.  Drug-binding proteins in liver transplant patients.

Authors:  M L Huang; R Venkataramanan; G J Burckart; R J Ptachcinski; D H Van Thiel; T E Starzl
Journal:  J Clin Pharmacol       Date:  1988-06       Impact factor: 3.126

6.  Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A.

Authors:  A Zeevi; R Duquesnoy; G Eiras; H Rabinowich; S Todo; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

7.  Biopharmaceutical aspects of FK-506.

Authors:  R Venkataramanan; V S Warty; M A Zemaitis; A T Sanghvi; G J Burckart; H Seltman; S Todo; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

8.  A highly sensitive method to assay FK-506 levels in plasma.

Authors:  K Tamura; M Kobayashi; K Hashimoto; K Kojima; K Nagase; K Iwasaki; T Kaizu; H Tanaka; M Niwa
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

9.  The question of FK 506 nephrotoxicity after liver transplantation.

Authors:  J McCauley; S Takaya; J Fung; A Tzakis; K Abu-Elmagd; A Jain; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

10.  Cyclosporin-erythromycin interaction in renal transplant patients.

Authors:  S K Gupta; A Bakran; R W Johnson; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335
View more
  38 in total

1.  Tacrolimus induced diabetic ketoacidosis in nephrotic syndrome.

Authors:  Sumantra Sarkar; Rakesh Mondal; Madhumita Nandi; Anjan Kumar Das
Journal:  Indian J Pediatr       Date:  2012-06-02       Impact factor: 1.967

Review 2.  Immunosuppressive drugs in renal transplantation. A review of the regimens.

Authors:  J M Barry
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

Review 3.  Liver transplantation.

Authors:  J Chiyende; A P Mowat
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

Review 4.  Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations.

Authors:  Simon Tremblay; Rita R Alloway
Journal:  AAPS J       Date:  2017-07-17       Impact factor: 4.009

5.  Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.

Authors:  Wai Johnn Sam; Lai San Tham; Michael J Holmes; Marion Aw; Seng Hock Quak; Kang Hoe Lee; Seng Gee Lim; Krishnan Prabhakaran; Sui Yung Chan; Paul C Ho
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

7.  Retrospective analysis of the correlation between tacrolimus concentrations measured in whole blood and variations of blood cell counts in patients undergoing allogeneic haematopoietic stem cell transplantation.

Authors:  Naoki Yoshikawa; Shuhei Urata; Kazuya Yasuda; Hiroshi Sekiya; Yasutoshi Hirabara; Manabu Okumura; Ryuji Ikeda
Journal:  Eur J Hosp Pharm       Date:  2018-11-16

Review 8.  A risk-benefit assessment of tacrolimus in transplantation.

Authors:  M Winkler; U Christians
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

9.  Tacrolimus analysis: a comparison of different methods and matrices.

Authors:  V Warty; S Zuckerman; R Venkataramanan; J Lever; J Chao; T Mckaveney; J Fung; T Starzl
Journal:  Ther Drug Monit       Date:  1995-04       Impact factor: 3.681

Review 10.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.